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Esthesioneuroblastoma (ENB) is a rare malignant tumour thought
to derive from neuroendocrine cells of the olfactory epithelium on
the basis of location, morphologic, immunophenotypic and ultra-
structural features. In fact, well differentiated ENB is character-
ized by the presence of neuropil, Homer Wright and olfactory
rosettes (Hyams et al, 1988), by a positive immunoreactivity for
neuron-specific enolase, synaptophysin, chromogranin and neuro-
filaments and, ultrastructurally, by cytoplasmic processes, micro-
tubules and dense core granules, all features consistent with an
origin in the olfactory epithelium (Shanmugaratnam, 1991;
Banerjee et al, 1992).
The neuroectodermal origin of ENB has been subsequently
strengthened by cytogenetic and molecular findings. The presence
of t(11;22)(q24;q12) translocation, the chromosome hallmark of
Ewing’s sarcoma, in addition to the single case of mesenchymal
chondrosarcoma, was detected repeatedly in three other tumours:
peripheral neuroepithelioma, Askin tumour and ENB (Heim et al,
1995). The presence of a common cytogenetic marker strength-
ened the hypothesis that all these four tumours are developmen-
tally related and that they represent phenotypic variations of the
same pathogenetic theme; for this reason they are defined as
primitive peripheral neuroectodermal tumours, Ewing’s tumours
(pPNETs-ETs). In ENB the t(11;22)(q24;q12) has been detected in
two out three metastatic cell lines (Whang-Peng et al, 1987;
Cavazzana et al, 1988) and the presence of trisomy 8, a second
non-random chromosomal aberration in pPNET-ETs, has been
found in one of three short-term cultures of primary ENB
(VanDevanter et al, 1991). The cytogenetic results were further
confirmed by the molecular analysis carried out by reverse tran-
scription polymerase chain reaction (RT-PCR) on six primary
ENBs (Sorensen et al, 1996). In four of them (two of which origi-
nated in the previously cited cell lines) (Cavazzana et al, 1988), the
presence of EWS/FLI-1 fusion transcript (Sorensen et al, 1994)
was identified.
However, these cytogenetic-molecular-based data have been
recently challenged by the results of two other studies. In the first
study (Nelson et al, 1995,) 18 out of 18 ENBs resulted non-
immunoreactively to the 12E7 monoclonal antibody, specific for
the protein product of the MIC2 gene and known to reliably stain
pPNETs-ETs, although not specifically (Chan et al, 1995). In the
second study, 20 out of 20 ENBs were immunocytochemically
MIC2-negative, and 11 of them were also EWS/FLI-1-negative for
the presence of fusion transcripts. Furthermore one case, analysed
by Southern blotting, did not show any EWS rearrangement
(Argani et al, 1998).
To address the point of whether ENB shares common markers
with pPNETs-ETs, we analysed five frozen samples of ENB, by
RT-PCR, dual colour fluorescence in situ hybridization (FISH) and
Southern blot. RT-PCR was performed to verify the occurrence of
the EWS/FLI-1 fusion transcript, of the EWS/ERG by RNA origi-
nated from the less frequent t(21;22)(q22;q12) translocation
reported in pPNETs-ETs (Sorensen et al, 1994), and of EWS/FEV
transcript related to the very rare variant t(2;22)(q33;q12) (Peter et
al, 1997). FISH on interphase nuclei was carried out in three cases
using cosmid probes flanking the fusion gene (EWS/FLI-1)
(Delattre et al, 1992; Zucman et al, 1992) and with a centromeric
probe for chromosome 8 (D8Z2) in order to determine the pres-
ence of the t(11;22)(q24;12) translocation (Desmaze et al, 1994)
and trisomy 8 respectively. Moreover, Southern blot analysis, with
a cDNA probe spanning the breakpoint cluster region of EWS,
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was carried out in three cases in order to verify the integrity of the
EWS gene.
None of the three different molecular approaches disclosed the
presence of any fusion transcripts or EWS rearrangements, neither
did immunohistochemistry detect any MIC2 positivity.
MATERIALS AND METHODS
Patients and tumours
The main clinico-pathologic features of the five patients under
analysis are summarized in Table 1. Categorization and grading
were performed according to the World Health Organization
(WHO) classification (Shanmugaratnam, 1991), and pre-therapy
staging according to the Kadish (1976) system.
Case 1 showed typical differentiated ‘neuroblastoma like’
growth pattern represented by nests of small round cells with retic-
ular areas formed by tangles of neurites emanating from tumour
cells. Areas with superimposable features were present in case II
which in addition presented solid nests made up of larger tumour
cells. The remaining three cases (III, V) were mainly made-up of
well-defined cellular nests or lobules of variable size of cells with
moderate pale eosinophilic cytoplasm with indistinct membranes
surrounded by fibrovascular septae. In particular, a moderate
amount of fibrillary background was present in case III and areas
forming interconnecting lobules of tumour cells in case V.
All cases with fibrillary stroma (cases I, II, III) showed rosettes,
whereas true olfactory (Flexner–Wintersteiner Wright) rosettes
were present only in case IV.
Immunocytochemistry
Immunophenotyping was carried out on formalin-fixed, paraffin-
embedded material in all cases and in appropiate positive and
negative controls using antibodies to the following antigens:
neuron-specific enolase (NSE) (MIG-N3, Sanbio, 1:400 diluted),
chromogranin (CRA237, Cambridge, 1:8000 diluted), synapto-
physin (AO10, Dako, 1:100 diluted), S-100 protein (polyclonal,
Dako, 1:4000 diluted), and cytocheratin and neurofilament (NF)
cocktails as well as p30/32MIC2 (HBA71, 0.13, Labometric,
1/100 diluted; and CD99, Signet, 1:100 diluted). The applied
cytocheratin (35b H11 Dako, and CAM 5.2 Becton-Dickinson,
1:100 and 1:20 diluted respectively) and neurofilament (RPN
1103, Amersham, and RPN 1104, Amersham, 1:33 and 1:50
diluted respectively) cocktails provided qualitative demonstration
of human cytocheratin numbers 8 and 18, and neurofilament
kDa 200 and 160 respectively. Antibody reactivity was visualized
using the biotin–streptavidin method (Wood et al, 1981). For
synaptophysin and cytocheratin antibodies, trypsin treatment of
the sections was carried out. For NSE, chromogranin, NF anti-
bodies and both HBA71 and CD99, heating-based antigen
retrieval (Cattoretti et al, 1992) prior to the application of the
primary antibody was applied.
Neuroendocrine markers and structural antigen immunopheno-
typing was consistent with the ENB diagnosis in all five cases
(Table 1) (Frierson, 1990; Shanmugaratnam, 1991). Diffuse posi-
tivity for NSE and strong reactivity for chromogranin and/or
synpatophysin was present in all five cases. Immunodecoration for
S-100 protein and NFs was restricted to dendritic-subtentacular
cells in five cases and neurophil formations in one. One case
revealed focal staining for cytokeratins.
Cytogenetic analysis
Metaphases obtained after the short-term (10 days) culture of case
III were G-banded, and the karyotype of nine metaphases was
determined.
FISH on metaphases
Whole chromosome 22 painting (Cambio, Cambridge, UK) was
hybridized, according to Pinkel et al (1986), on the metaphases
from case III in order to confirm the cytogenetic results.
FISH on interphase nuclei
Probes
F7 cosmid probes, located distal to the 22 chromosome breakpoint,
and 1p3, which proximally flanks and overlaps half the breakpoint
on chromosome 11 (Delattre et al, 1992; Zucman et al, 1992), were
labelled by nick translation. Biotin-11-dUTP (Boehringer
Mannheim, Germany) was incorporated in F7, and digoxigenin-11-
dUTP (Boehringer Mannheim, Germany) in 1p3; 50 ng of both
probes were then annealed to 5 mg of unlabelled human competitor
DNA to suppress the repetitive sequences, and to 5 mg of carrier
salmon sperm DNA. Botinylated chromosome 8 2-satellite (Oncor,
Gaithersburg, MD, USA) was used for the detection of chromo-
some 8 trisomy according to the manufacturer’s recommendations.
Table 1 Clinico-pathological features of the five ENBs
Immunostaining
Neuroendocrine markers/structural antigens
Case Age/Sex Site Sampling Grading Staging NSE Ch. Syn. S-100p CKs NFs MIC2
(WHO) (Kadish)
1 35/F Ethmoid Complete surgical resection 2 A +++ +++ +++ + – + –
2 70/M Ethmoid, maxillary sinus Incomplete surgical resection 3 B +++ +++ +++ + – – –
3 50/F Ethmoid, maxillary sinus Incomplete surgical resection 3 C +++ +++ +++ + – – –
4 22/M Ethmoid Wide biopsy 3 C +++ – + + + – –
5 37/F Nasal cavity Wide biopsy 4 C +++ +++ + + – – –
Score applied to chromogranin, synaptophysin: positive cells < 20%: +; > 90%: +++. For neuron specific enolase, S-100 protein, cytocheratin and
neurofilaments, see text.588 A Mezzelani et al
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FISH
FISH was performed as previously described by Lichter and
collaborators (1990) on cases I, III and IV. Independent experi-
ments with a chromosome 8 centromeric probe and with F7 and
1p3 cosmid probes were performed respectively.
The hybridization signals of chromosome 8 2-satellite were
detected by two layers of avidin–FITC (Vector, Burlingame, CA,
USA). The signals of the F7 and 1p3 cosmids were simultaneously
detected by two layers of avidin–FITC (which bound to the
biotinylated F7 probe) and one layer of rhodamine-labelled
anti-digoxigenin (Ab) followed by rabbit anti-sheep (Ab),
and finally by rhodamine-labelled anti-rabbit (Ab) (Oncor,
Gaithersburg, MD, USA) which bound to the digoxigenin of the
1p3 probe. Slides were then counterstained by DAPI (4,6,-
diamidino-2-phenylindole dihydrochloride hydrate).
Digital signal detection
Image acquisition was performed with a cooled CCD camera
(Photometrics, Tucson, AZ, USA) coupled with a Zeiss fluores-
cence microscope and controlled by a Power Macintosh 7100/80.
Frames of the nuclei were taken separately using the IPLab
Spectrum (Signal Analytics) software package, and pseudo-
coloured and merged using the Gene Join software (Ried et al,
1992).
RT-PCR
A frozen tumour fragment from all cases as well as from two
Ewing’s tumours (ETs) with the EWS/FLI-1 and EWS/ERG
fusion transcripts, respectively, representing positive controls, was
mechanically disaggregated and total RNA was isolated using the
RNAzolB extraction system (TEL-TEST, TX, USA). No positive
control was available for the EWS/FEV fusion gene. RNA was
also extracted from a normal mesenchymal tissue to be used as
negative control. One microgram of total RNA was reverse-tran-
scribed into cDNA using oligo(dT) primers and reverse transcrip-
tase (Superscript, Gibco-BRL) according to the manufacturer’s
recommendations.
Control amplification of cDNAs was accomplished by using b-
actin specific primers (Adams, 1995) and wild-type EWS primers.
The detection of the putative EWS/FLI-1, EWS/ERG junction
regions was carried out using primers 11.11 and 22.8 (Zucman et
al, 1993) and Erg11 (Delattre et al, 1994) and 22.8 respectively.
The PCR reaction consisted of denaturation at 94°C for 30 s,
annealing at 68°C for 1 min and elongation at 72°C for 1 min.
Thirty-five cycles were performed. The detection of the putative
EWS/FEV was carried out using primers EWS22.14 and Fev 11 at
the following PCR conditions: 35 cycles consisting of denaturation
at 94°C for 30 s, annealing at 65°C for 1 min and elongation at
72°C for 1 min (Peter et al, 1997). The amplification products
were analysed on 2% TBE1X-agarose gel.
Southern blot
DNA was extracted from cases I, II and IV, as well as from two
positive controls containing the EWS/FLI-1 transcript, using the
Genomix extraction kit (Talent, Trieste, Italy). Ten micrograms of
genomic DNA were digested with EcoRI, HindIII, BamHI, SacI
and Xhol. Restriction fragments were separated by electrophoresis
in 0.8% agarose gel O.N. and transferred to nylon membranes
(Hybond-N+; Amersham) by standard methods. Filters were
hybridized overnight with a (32P) radiolabelled probe to a high
specific activity by random priming (Prime-it Random Primer
Labeling Kit, Stratagene). The EWS probe used was a 593 base
pair partial cDNA probe generated by standard PCR. This probe
corresponds to nucleotides 720–1313 of the EWS cDNA and
includes exons 7–12, which constitute the genomic EWS break-
point cluster region in pPNETs-ETs (Delattre et al, 1992). The
hybridized filters were washed at high stringency and exposed for
2–7 days. Placental DNA was used as normal control and DNAs
from two cases with EWS/FLI-I rearrangements were included as
positive controls.
A
B
C
D
Figure 1 Case III. (A and B) Two interphase nuclei showing the separated
signals of F7 cosmid probes (white spots–white arrows), located distal to the
22 chromosome breakpoint, and 1p3 (black spots–black arrows), that
proximally flanks and overlaps half the breakpoint on chromosome 11. When
nuclei are in the G2 phase, the spots appear in pairs. (C) One interphase
nucleus with three centromeric signals (white arrows) of chromosome 8.
(D) One interphase nucleus with four centromeric signals (white arrows) of
chromosome 8
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Figure 2 RT-PCR results. MW: the molecular weight marker is 1 kb.
EWS/FLI-1: samples 1–5 were tumour cDNA from cases I–V, sample 6 was
tumour cDNA used as positive control for EWS/FLI-1 fusion transcript
(500 bp), sample 7 was cDNA from normal tissue used as negative control,
and sample 8 was the reaction mixture without cDNA; all were amplified by
the EWS/FLI-1 primers 11.11 and 22.8. EWS/ERG: samples 1–8 are the
same samples, except for the positive control that contains cDNA from
EWS/ERG fusion transcript (490 bp), amplified by the EWS/ERG primers
ERG11 and 22.8 EWS/FEV: samples 1–5 were tumour cDNA from cases
I–V, sample 6 was the negative control and sample 7 was the reaction
mixture without cDNANo track of pPNETs-ETs markers in esthesioneuroblastoma 589
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RESULTS
By immunohistochemistry the five ENB cases were negative both
with the monoclonal antibody HBA71 and CD99 specific for the
protein products of the MIC2 gene.
The cytogenetic analysis of case III resulted in a normal
karyotype, and did not reveal numerical and/or structural
chromosome abnormalities or the reciprocal t(11;22)(q24;q12),
t(21;22)(q22;q12), t(7;22)(p22;q12), t(17;22)(q12;q12) and the
t(2;22)(q33;q12) translocations (Rao et al, 1987; Sorensen et al,
1994; Jeon et al, 1995; Kaneko et al, 1996; Peter et al, 1997), or
trisomy 8. These results were confirmed by a FISH experiment on
metaphase spreads by using a chromosome 22 painting probe
which detected two normal chromosome 22 (data not shown).
One hundred interphase nuclei were scored for each case with
dual colour FISH using the F7 and 1p3 cosmids flanking the
EWS/FLI-1 fusion gene. The absence of t(11;22)(q24;q12) was
confirmed in all the three patients analysed: the four signals, two
green signals corresponding to F7 probe and two red signals corre-
sponding to 1p3 probe were found apart (Figure 1 A, B). The same
experiment performed on a series of Ewing’s tumours with a
t(11;22), used as positive contol, showed a green/red double spot
corresponding to the fusion gene (data not shown).
FISH experiments using a centromeric probe excluded trisomy
8 in cases I and IV, while two different clones were found in case
III: one containing three copies of chromosome 8 and the other
four (Figure 1 C, D).
RT-PCR analysis using EWS/FLI-1, EWS/ERG and EWS/FEV
primers did not detect fusion transcripts in any of the five ENB
cases (Figure 2), whereas the positive controls for the first two
tranlocations showed the expected specific transcripts. No positive
control was available for the EWS/FEV fusion. All the samples
showed the expected products when amplified by b-actin specific
primers and wild-type EWS primers (Figure 3).
By Southern blot none of the three cases analysed showed any
EWS rearrangement after digestion with EcoR1, HindIII, SacI
and  XhoI enzymes, while the two positive controls carrying a
t(11;22) and t(21;22) showed a rearranged fragment of 19 and
21 kb and 20 kb respectively, after digestion with SacI and XhoI
enzymes respectively (Figure 4).
DISCUSSION
Esthesioneuroblastoma is a malignant tumour characterized by vari-
able histology and conflicting immmunophenotyping, cytogenetic
and molecular data. Some authors assert the belonging of ENB to
the pPNETs-ETs group of tumours through cytogenetic (Whang-
Peng et al, 1987; Cavazzana et al, 1988; VanDevanter et al, 1991) or
molecular evidence (Sorensen et al, 1996), whereas others disagree
because of opposite immunophenotypic (Nelson et al, 1995) and/or
molecular results (Mezzelani et al, 1997; Argani et al, 1998).
In order to address this issue we analysed five consecutive cases
of ENB tumour specimens using both cytogenetic and molecular
b–actin EWS
MW
396
123456 123456
Xhol Sacl
MW 1 2 3 4 5
23.74
9.5
6.7
4.3
12 3 45
Figure 3 RT-PCR results. MW: the molecular weight marker is 1 kb. For both b-actin and EWS amplification, samples 1–5 were tumour cDNA from cases I–V,
sample 6 was cDNA from normal tissue
Figure 4 Southern blot results. MW: the molecular weight marker was l HindIII. For both XhoI and SacI digestion, samples 1 and 2 were the two positive
controls and samples 3–5 were case I, II and IV respectivelytechniques. All cases were consistent with olfactory neuroblast-
oma in terms of morphology and tumour-specific immunopheno-
type, as well as development site and clinical presentation.
As for MIC2 gene expression, all our cases showed null MIC2
gene immunophenotype, in agreement with the recent report of
Nelson et al (1995). Furthermore, the results we obtained on the
original uncultured tumour specimens by dual colour FISH in
cases I, III and IV, RT-PCR in all cases, and by Southern blot in
cases I, II and IV all confirmed the absence of any EWS rearrange-
ments. In fact we did not find any evidence of EWS/FLI-1 fusion
gene by FISH on interphase nuclei, or of EWS/FLI-1 fusion tran-
scripts, or of EWS/ERG and EWS/FEV variants by cDNA ampli-
fication. The same was true for Southern blot analysis that
confirmed the EWS gene integrity. Case III was the only tumour
whose cells were successfully cultured in vitro short-term culture.
The culture was harvested after 10 days, and the metaphases
showed a normal 46,XY karyotype. Since it has been reported that
during the in vitro culture fibroblasts could overgrow tumour cells
(Jin et al, 1995), we must take this potential bias into account.
We attribute the robustness of our approach to three factors.
First, the reliability of the RT-PCR results are based on the fact that
the cDNA adequacy was tested by both b-actin and EWS amplifi-
cation as well as on the amplification of positive controls. Second,
even though in theory, rearrangements of the EWS locus could be
excluded only by complete sequencing of the tumour DNA, we
undertook an extended Southern blot analysis. In our experience,
pPNETs-ETs DNA carrying EWS/FLI-1 transcript does not
always show EWS rearrangement when digested by EcoR1 and
HindIII enzymes. In fact, only the use of rare cuttering enzymes,
such as SacI and XhoI, allowed us to demonstrate the presence of
EWS rearrangements in these samples and thus to ultimately
exclude the presence of rearrangements in our ENB cases. Third,
FISH allowed a cell by cell analysis that excluded the presence of
the EWS/FLI-1 transcript in the three tested ENB and, by contrast,
showed it in a series of pPNETs-ETs.
The presence, in Case III, of two different clones containing
three and four copies of chromosome 8, respectively, is not suffi-
ciently understood. Although, trisomy 8 is described as the most
common secondary anomaly in neuroectodermal tumours (Heim
and Mitelman, 1995), it is also a frequent abnormality in different
tumour types. In fact, trisomy 8 is a non-random secondary change
in other soft tissue tumours, such as clear cell sarcoma (Travis et
al, 1992) and myxoid liposarcoma (Sreekantaiah et al, 1994) and
appears as the only chromosome abnormality in several myeloid
and lymphoid disorders (Mitelman, 1985; Haim and Mitelman,
1995) along with superficial and deep fibromatosis (Somers et al,
1987; Dal Cin et al, 1994).
In conclusion, on the basis of our data and a critical analysis of
the literature, we are inclined to assert that ENB may represent a
distinct entity as opposed to being a member of the pPNETs-ETs.
In fact, only four out of 27 ENB cases (Wang-Peng et al, 1987;
Cavazzana et al, 1988; Sorensen et al, 1996) cytogenetically or
molecularly analysed, showed the EWS/FLI-1 fusion gene. As
already argued (Nelson et al, 1995) two of the three ENB cell lines
described to carry the t(11;22)(q24;q12)-derived EWS/FLI-1
fusion transcript (Whang-Peng et al, 1987; Cavazzana et al, 1988;
Sorensen et al, 1996) probably represent metastatic lesions
deriving from a primary pPNET-ET in the chest wall and in the
paraspinal region, respectively, and metastasizing to the nasal
cavity. Two additional primary ENBs described by Sorensen et al
(1996) could represent pPNETS-ETs or extraskeletal ETs arising
in the nasal fossa, as previously described by Pontius and Sebek
(1982), and Lane and Ironside (1990). The remaining three cases
with abnormal karyotype described by other authors did not show
a t(11;22) translocation (Castaneda et al, 1991; Van Devanter et al,
1991; Jin et al, 1995). Finally, the immunophenotypic data from 43
cases were all consistent with a lack of MIC2 protein product
(Nelson et al, 1995; Argani et al, 1998).
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